Immuneering Corp. (IMRX)
4.58
-0.20
(-4.18%)
USD |
NASDAQ |
Sep 09, 15:46
Immuneering Total Liabilities (Quarterly) : 11.32M for June 30, 2026
Total Liabilities (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Total Liabilities (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 11.32M |
| March 31, 2026 | 8.292M |
| December 31, 2025 | 13.50M |
| September 30, 2025 | 13.08M |
| June 30, 2025 | 11.12M |
| March 31, 2025 | 8.838M |
| December 31, 2024 | 11.33M |
| September 30, 2024 | 10.84M |
| June 30, 2024 | 10.78M |
| March 31, 2024 | 9.260M |
| December 31, 2023 | 12.01M |
| September 30, 2023 | 9.863M |
| Date | Value |
|---|---|
| June 30, 2023 | 9.791M |
| March 31, 2023 | 9.907M |
| December 31, 2022 | 12.52M |
| September 30, 2022 | 11.80M |
| June 30, 2022 | 8.455M |
| March 31, 2022 | 8.391M |
| December 31, 2021 | 10.72M |
| September 30, 2021 | 5.749M |
| June 30, 2021 | 88.23M |
| March 31, 2021 | 61.39M |
| December 31, 2020 | 60.95M |
Total Liabilities Definition
Liabilities are a main portion of the balance sheet of a company that measure outstanding payables/obligations. A few examples of liabilties of a company include accounts payable, current debt, and capital lease obligations. From an accounting perspective, the balance sheet equation is Liabilties = Assets - Shareholder's Equity.
Total Liabilities (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Total Liabilities (Quarterly) Benchmarks
| Regeneron Pharmaceuticals, Inc. | 10.02B |
| ACADIA Pharmaceuticals, Inc. | 436.29M |
| Alnylam Pharmaceuticals, Inc. | 4.205B |
| Anika Therapeutics, Inc. | 46.19M |
| Savara, Inc. | 48.48M |
Total Liabilities (Quarterly) Related Metrics
| Total Assets (Quarterly) | 202.06M |
| Shareholders Equity (Quarterly) | 190.74M |
| Debt to Equity Ratio | 0.0191 |
| Current Ratio | 19.47 |
| Net Debt Paydown Yield | 0.03% |